BiotechTube
Home/Pipeline/RGI-AB-02

RGI-AB-02

Solid Tumor

PreclinicalActive

Key Facts

Indication
Solid Tumor
Phase
Preclinical
Status
Active
Company
REGiMMUNE

About REGiMMUNE

Treg‑focused biotech delivering novel immunotherapies for GvHD, autoimmunity and oncology.

View full company profile

Therapeutic Areas

OncologyImmunology

Other Solid Tumor Drugs

DrugCompanyPhase
AV-203AVEO OncologyPre-clinical
LR19155AVEO OncologyPre-clinical
LR20011AVEO OncologyPre-clinical
LR19129AVEO OncologyPre-clinical
LR19023AVEO OncologyPre-clinical
Undisclosed Transcription FactorTalus BioscienceDiscovery
RGI-AB-01REGiMMUNEPreclinical
RGI-AB-03REGiMMUNEPreclinical
RGI-AB-04REGiMMUNEPreclinical
CS028Lumosa TherapeuticsPre‑clinical